Edition:
India

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

2.93USD
17 Nov 2017
Change (% chg)

$0.02 (+0.69%)
Prev Close
$2.91
Open
$2.86
Day's High
$2.94
Day's Low
$2.86
Volume
246,423
Avg. Vol
158,773
52-wk High
$3.23
52-wk Low
$1.01

Latest Key Developments (Source: Significant Developments)

Catalyst Pharmaceuticals posts Q3 loss per share $0.05
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Catalyst Pharmaceuticals Inc :Catalyst Pharmaceuticals announces third quarter 2017 financial results and provides corporate update.Q3 GAAP loss per share $0.05.Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.Catalyst Pharmaceuticals Inc - ‍expects pre-commercialization expenses to increase in Q4 of 2017​.  Full Article

Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse®
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Catalyst Pharmaceuticals Inc :Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse® in patients with Lambert-Eaton Myasthenic Syndrome.Catalyst Pharmaceuticals Inc - ‍top-line results for Phase 3 trial of Firdapse expected in early December​.  Full Article

Catalyst Pharmaceuticals announce Q2 2016 financial results and provides product development update
Wednesday, 10 Aug 2016 

Catalyst Pharmaceuticals Inc : Catalyst Pharmaceuticals announces second quarter 2016 financial results and provides product development update . Q2 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S . Q2 GAAP loss per share $0.06 .Q2 non-GAAP loss per share $0.06 excluding items.  Full Article

Catalyst Pharma finalizes late-stage trial design with FDA for Firdapse
Monday, 13 Jun 2016 

Catalyst Pharmaceuticals Inc : Catalyst Pharmaceuticals announces agreement with FDA on confirmatory phase 3 study protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome . Expects to initiate a small, single-center study with Firdapse during second half of 2016 .Existing capital resources are adequate to get us to an accepted NDA submission without need for additional financing.  Full Article

Catalyst Pharmaceuticals announces reduction in workforce
Tuesday, 17 May 2016 

Catalyst Pharmaceuticals Inc : Announces reduction in workforce as part of operating expense management plan . Reducing its workforce by approximately 30% . Expects to complete reduction in workforce immediately . Reduction in workforce affects employees from Catalyst's commercial team . Believe currently available resources will be sufficient to complete development of and refile NDA for firdapse for lems, cms .Reduction in workforce is part of ongoing efforts to conserve cash to complete requirements for NDA submission of Firdapse.  Full Article

Catalyst Pharmaceuticals posts Q1 GAAP loss of $0.07/shr
Wednesday, 11 May 2016 

Catalyst Pharmaceuticals Inc : Believe current resources give sufficient runway for at least next year . Continue to believe available resources will be sufficient to complete development of firdapse, refile nda for firdapse . Catalyst pharmaceuticals announces first quarter 2016 financial results and provides corporate update . Q1 gaap loss per share $0.07 . Q1 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S .Q1 non-gaap loss per share $0.07 excluding items.  Full Article

Catalyst Pharmaceuticals announces top-line results in Phase 1 Trial of CPP-115
Wednesday, 16 Dec 2015 

Catalyst Pharmaceuticals Inc:Says main adverse effect of prolonged elevated brain gaba, somnolence, was also observed.Results showed significant increases in brain levels of surrogate marker for potential efficacy, gamma-aminobutyric acid.Says expect to receive the full results of this study early next year.  Full Article

BRIEF-Catalyst Pharmaceuticals posts Q3 loss per share $0.05

* Catalyst Pharmaceuticals announces third quarter 2017 financial results and provides corporate update